Elstar Therapeutics is fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating antibody-based, multi-functional therapeutics. Armed with a unique approach to engaging multiple immune mechanisms, Elstar enables patients to harness their own body to fight cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/03/18 | $39,000,000 | Series A |
Apple Tree Partners | undisclosed |
